Choline
- Generic Name
- Choline
- Brand Names
- Alertonic
- Drug Type
- Small Molecule
- Chemical Formula
- C5H14NO
- CAS Number
- 62-49-7
- Unique Ingredient Identifier
- N91BDP6H0X
- Background
A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.
- Indication
For nutritional supplementation, also for treating dietary shortage or imbalance
- Associated Therapies
- Nutritional supplementation
Comparison of the Effects of Oral Ulceration Healing in Patients Wearing a Removable Denture
- Conditions
- Oral Mucosa; Ulcer
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Medical University of Silesia
- Target Recruit Count
- 27
- Registration Number
- NCT06531720
- Locations
- 🇵🇱
Department of TMD Silesian Medical University, Zabrze, Poland
Choline and Iron Deficiency
- Conditions
- AnemiaPediatric Iron Deficiency
- Interventions
- Other: placebo drug
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 300
- Registration Number
- NCT06527391
Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 140
- Registration Number
- NCT06379971
- Locations
- 🇺🇸
UC Health, Aurora, Colorado, United States
Effects of a Nutraceutic Compound on Cognitive Impairment
- Conditions
- Mild Cognitive Impairment
- Interventions
- Drug: Placebo oral vial
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 58
- Registration Number
- NCT06200883
- Locations
- 🇮🇹
Ambulatorio Ipertensione e Unità Coronarica Federico II University, Napoli, Italy
Choline Effects - Pre-symptomatic AD
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Paul E Schulz
- Target Recruit Count
- 14
- Registration Number
- NCT05880849
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, United States
Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Daewoong Bio Inc.
- Target Recruit Count
- 630
- Registration Number
- NCT05383183
- Locations
- 🇰🇷
Changwon Fatima Hospital, Changwon, Korea, Republic of
🇰🇷CHA Bundang Medical Center, Seongnam, Korea, Republic of
🇰🇷The Catholic University of Korea Seoul ST.MARY'S Hospital, Seoul, Korea, Republic of
Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
- Conditions
- AtherosclerosisDiabetes Mellitus, Type 2Dyslipidemia
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT05365425
- Locations
- 🇰🇷
SNUBH, Seongnam, Gyeonggi, Korea, Republic of
Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders Study
- Conditions
- Fetal Alcohol Spectrum Disorders
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Jeff Wozniak
- Target Recruit Count
- 60
- Registration Number
- NCT05108974
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Reverse Triple Negative Immune Resistant Breast Cancer
- Conditions
- Triple-negative Breast Cancer
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05076682
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients
- Conditions
- Vascular Cognitive Impairment
- Interventions
- Drug: Placebo of Choline Alfoscerate 400mg
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 418
- Registration Number
- NCT05050604
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.